Metrics as of 10/13/2026, 06:53 PM (Berlin time), refresh in progress.
Karyopharm Therapeutics Stock
Karyopharm Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Richard A. Paulson
- Employees
- 228
- Market cap
- $9 M
- IPO
- 06/11/2013
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves…
Karyopharm Therapeutics stock: price history
1D
+11.2%
1W
-35.5%
1M
-77.1%
6M
-95.5%
YTD
-94.7%
1Y
-93.5%
2Y
-96.9%
5Y
-99.5%
10Y
-99.7%
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~29% stronger price swings than usual
Ask the agents about Karyopharm Therapeutics
Analyst assessment of Karyopharm Therapeutics
PRICE TARGET LOW
US$3.00
CONSENSUS
US$9.50
MEDIAN
US$9.50
PRICE TARGET HIGH
US$16.00
0
STRONG BUY
13
BUY
5
HOLD
2
SELL
0
STRONG SELL
20
TOTAL · Buy
As of: 31/07/2026
Karyopharm Therapeutics stock metrics
P/E
-0.02
P/B
-0.03
EV/EBITDA
-0.97
RETURN ON EQUITY
20.3%
NET MARGIN
-200.5%
DEBT/EQUITY
-0.65
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
65.4%
FLOAT SHARES
14,812,046
AVG. DAILY VOLUME (30D)
1,526,789
Insider transactions (SEC)
Abate Kristin
Abate Kristin
Poulton Stuart
Schor Chen
Oliger Christy J.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Karyopharm Therapeutics stock
What does Karyopharm Therapeutics do?
Karyopharm Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Richard A. Paulson, the company employs around 228 people.
The IPO was on 06/11/2013; the stock trades on NASDAQ under the ticker KPTI.
What do analysts say about Karyopharm Therapeutics stock?
20 analysts rate the stock, the consensus is Buy (as of 31/07/2026).
The average price target is US$9.50, ranging from US$3.00 to US$16.00, with a median of US$9.50.
This is an external assessment, not a statement by Market Jury.
When does Karyopharm Therapeutics report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 29% stronger than usual.
Does Karyopharm Therapeutics pay a dividend?
No, Karyopharm Therapeutics currently does not pay a dividend.
Which stocks are comparable to Karyopharm Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Karyopharm Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Karyopharm Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.